SHIJIAZHUANG, China, July 1, 2020 /PRNewswire/ -- Following Thailand, Singapore and Indonesia, Yiling Pharmaceutical (002603.SZ), a leader in the development of traditional Chinese medicines (TCM), obtained a Certificate of Registration issued by the Drug Department of Laos' Ministry of Health which registers Lianhua Qingwen Capsule as Chinese Proprietary Medicine (CPM).
In its latest move, Beijing health authorities have included Chinese medicine into the treatment plan for COVID-19 patients, as the city is going through a resurgence of the novel coronavirus after a 56-day streak of no locally transmitted cases.
Yiling Pharma's products get overseas health bodies' nods for market access.As the COVID-19 epidemic situation worsened overseas, Koh Chok Tong, a 35-year-old engineer in Singapore, felt he was lucky enough to be able to buy Lianhuaqingwen capsules manufactured by Shijiazhuang, Hebei province-based Chinese drug firm Yiling Pharmaceutical at a local pharmacy.
Clinical observation in designated COVID-19 hospitals in China has showed that TCM including the Lianhua Qingwen Capsule are effective in the treatment of over 90 percent of all confirmed COVID-19 cases on the Chinese mainland.
Developed under the guidance of collateral disease theory, the medicine is listed as the recommended medicine for the treatment of cold and influenza by China’s National Health Commission and National Administration of Traditional Chinese Medicine. Composed of 13 Chinese herbs, the TCM has been found in the clinical research that it is effective in alleviating the influenza-induced symptoms like fever, cough and fugue.